- VGXI has joined the Rapid Response Partnership Vehicle (RRPV), aiding BARDA in medical countermeasure development.
- The company brings extensive experience in plasmid DNA manufacturing and has the world’s largest plasmid production capacity.
VGXI, Inc., a contract developer and manufacturer (CDMO) specialising in nucleic acid biopharmaceuticals, has been selected to join the Rapid Response Partnership Vehicle (RRPV). This partnership supports the Biomedical Advanced Research and Development Authority (BARDA) in accelerating the development of medical countermeasures (MCMs) for pandemics, emerging diseases, and other biological threats.
The announcement was made on July 30, 2024. VGXI will contribute to RRPV’s efforts by leveraging its extensive expertise in plasmid DNA manufacturing, which includes the world’s largest plasmid production capacity at 4000 litres from its two facilities spanning 160,000 square feet.
Young Park, CEO of VGXI, commented on the development: “We are honoured to be accepted as a member of RRPV. With our track record in manufacturing vaccines for diseases like Influenza, Ebola, MERS, and COVID-19, we are eager to support RRPV members and US Government partners in combating future pandemics. VGXI is ready for partnerships to enhance nucleic acid-based manufacturing and offer end-to-end solutions.”
Overview of outsourcing trends 
